Swiss Biotech Association reports CHF 7.5 billion revenue for Switzerland’s biotech Industry in 2025
The private funding rose 38% amid growing international collaborations and CDMO demand
The private funding rose 38% amid growing international collaborations and CDMO demand
Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
Subscribe To Our Newsletter & Stay Updated